Daidzein promotes glucose uptake through glucose transporter 4 translocation to plasma membrane in L6 myocytes and improves glucose homeostasis in Type 2 diabetic model mice

Journal of Nutritional Biochemistry

Volumn 25, Issue 2, 2014, Pages 136-143

  Cheong, Sun Hee ^a,b   Furuhashi, Keisuke ^a   Ito, Katsuki ^a   Nagaoka, Masato ^a   Yonezawa, Takayuki ^c   Miura, Yutaka ^a   Yagasaki, Kazumi ^a,c  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b Konkuk University   (South Korea)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

AMPK; Daidzein; Glucose transporter 4; Glucose uptake; L6 myocytes

Indexed keywords

ADENYLATE KINASE; CHOLESTEROL; COMPLEMENTARY DNA; DAIDZEIN; GLUCOSE; GLUCOSE TRANSPORTER 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; GLUCOSURIA; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; MUSCLE FIBER MEMBRANE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASE; AMPK; DAIDZEIN; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 4.; GLUCOSE UPTAKE; GLUT4; L6 MYOCYTES;

ADENYLATE KINASE; ANIMALS; BASE SEQUENCE; CELL MEMBRANE; DIABETES MELLITUS, TYPE 2; DNA PRIMERS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; ISOFLAVONES; MICE; MUSCLE CELLS; PHOSPHORYLATION; PROTEIN TRANSPORT;

EID: 84892558969     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.09.012     Document Type: Article

References (44)

1. International Diabetes Federation, Diabetes voice 2012, 57.
2. Kopelman P.G. Obesity as a medical problem. Nature 2000, 404:635-643.
3. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
4. Goodman-Gruen D., Kritz-Silverstein D. Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J Nutr 2001, 131:1202-1206.
5. Davis J., Higginbotham A., O'Connor T., Moustaid-Moussa N., Tebbe A., Kim Y.C., et al. Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat. Ann Nutr Metab 2007, 41:42-52.
6. Park S.A., Choi M.S., Cho S.Y., Seo J.S., Jung U.J., Kim M.J., et al. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice. Life Sci 2006, 79:1207-1213.
7. Guilherme A., Virbasius J.V., Puri V., Czech M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9:367-377.
8. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-415.
9. Wood I.S., Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003, 89:3-9.
10. Vera J.C., Reyes A.M., Velásquez F.V., Rivas C.I., Zhang R.H., Strobel P., et al. Direct inhibition of the hexose transporter GLUT1 by tyrosine kinase inhibitors. Biochem. 2001, 40:777-790.
11. Abler A., Smith J.A., Randazzo P.A., Rothenberg P.L., Jarett L. Genistein differentially inhibits postreceptor effects of insulin in rat adipocytes without inhibiting the insulin receptor kinase. J Biol Chem 1992, 267:3946-3951.
12. Wright D.C., Geiger P.C., Han D.H., Holloszy J.O. Are tyrosine kinases involved in mediating contraction-stimulated muscle glucose transport?. Am J Physiol Endocrinol Metab 2006, 290:E123-E128.
13. Cederroth C.R., Vinciguerra M., Gjinovci A., Kühne F., Klein M., Cederroth M., et al. Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes 2008, 57:1176-1185.
14. Yagasaki K., Morisaki N., Kitahara Y., Miura A., Funabiki R. Involvement of protein kinase C activation in L-leucine-induced stimulation of protein synthesis in L6 myotubes. Cytotechnology 2003, 43:97-103.
15. Kawano A., Nakamura H., Hata S., Minakawa M., Miura Y., Yagasaki K. Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice. Phytomedicine 2009, 16:437-443.
16. Nishiumi S., Ashida H. Rapid preparation of a plasma membrane fraction from adipocytes and muscle cells: application to detection of translocated glucose transporter 4 on the plasma membrane. Biosci Biotechnol Biochem 2007, 71:2342-2346.
17. Minakawa M., Miura Y., Yagasaki K. Piceatannol, a resveratrol derivative, promotes glucose uptake through glucose transporter 4 translocation to plasma membrane in L6 myocytes and suppresses blood glucose levels in type 2 diabetic model db/db mice. Biochem Biophys Res Commun 2012, 422:469-475.
18. Arunkumar E., Anuradha C.V. Genistein promotes insulin action through adenosine monophosphate-activated protein kinase activation and p70 ribosomal protein S6 kinase 1 inhibition in the skeletal muscle of mice fed a high energy diet. Nutr Res. 2012, 32:617-625.
19. Hayashi T., Hirshman M.F., Kurth E.J., Winder W.W., Goodyear L.J. Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998, 47:1369-1373.
20. Kurth-Kraczek E.J., Hirshman M.F., Goodyear L.J., Winder W.W. 5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 1999, 48:1667-1671.
21. Lee H.M., Lee O.H., Kim K.J., Lee B.Y. Ginsenoside Rg1 promotes glucose uptake through activated AMPK pathway in insulin-resistant muscle cells. Phytother Res 2012, 26:1017-1022.
22. Clarkson T.B. Soy, soy phytoestrogens and cardiovascular disease. J Nutr 2002, 132:566S-569S.
23. Jayagopal V., Albertazzi P., Kilpatrick E.S., Howarth E.M., Jennings P.E., Hepburn D.A., et al. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 2002, 25:1709-1714.
24. Bhathena S.J., Velasquez M.T. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 2002, 76:1191-1201.
25. Nanri A., Mizoue T., Takahashi Y., Kirii K., Inoue M., Noda M., et al. Soy product and isoflavone intakes are associated with a lower risk of type 2 diabetes in overweight Japanese women. J Nutr 2010, 140:580-586.
26. Lee D.S., Lee S.H. Genistein, a soy isoflavone, is a potent α-glucosidase inhibitor. FEBS Lett 2001, 501:84-86.
27. Cavaghan M.K., Ehrmann D.A., Polonsky K.S. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000, 106:329-333.
28. Ha B.G., Nagaoka M., Yonezawa T., Tanabe R., Woo J.T., Kato H., et al. Regulatory mechanism for the stimulatory action of genistein on glucose uptake in vitro and in vivo. J Nutr Biochem 2012, 23:501-509.
29. Kirk E.A., Sutherland P., Wang S.A., Chait A., LeBoeuf R.C. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL receptor-deficient mice. J Nutr 1998, 128:954-959.
30. Uesugi T., Fukui Y., Yamori Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: a four-week study. J Am Coll Nutr 2002, 21:97-102.
31. Kim M.H., Kang K.S., Lee Y.S. The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease. Br J Nutr 2010, 104:1333-1342.
32. Ito T., Tanimoto M., Yamada K., Kaneko S., Matsumoto M., Obayashi K., et al. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology (Carlton). 2006, 11:29-35.
33. Berasi S.P., Huard C., Li D., Shih H.H., Sun Y., Zhong W., et al. Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase. J Biol Chem 2006, 281:27167-27177.
34. Basu R., Chandramouli V., Dicke B., Landau B., Rizza R. Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes 2005, 54:1942-1948.
35. Choi M.S., Jung U.J., Yeo J., Kim M.J., Lee M.K. Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice. Diabetes Metab Res Rev 2008, 24:74-81.
36. Son M.J., Minakawa M., Miura Y., Yagasaki K. Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic ob/ob mice. Eur J Nutr 2013, 52:1607-1619.
37. Minakawa M., Kawano A., Miura Y., Yagasaki K. Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5 F pancreatic β-cells. J Clin Biochem Nutr 2011, 48:237-244.
38. Tennen R.I., Michishita-Kioi E., Chua K.F. Finding a target for resveratrol. Cell 2012, 148:387-389.
39. Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148:421-433.
40. Kuppusamy U.R., Das N.P. Effects of flavonoids on cyclic AMP phosphodiesterase and lipid mobilization in rat adipocytes. Biochem Pharmacol 1992, 44:1307-1315.
41. Pan L., Xia X., Feng Y., Jiang C., Huang Y. Exposure to the phytoestrogen daidzein attenuates apomorphine-induced penile erection concomitant with plasma testosterone level reduction in dose and time-related manner in adult rats. Urology 2007, 70:613-617.
42. McClain R.M., Wolz E., Davidovich A., Pfannkuch F., Bausch J. Reproductive safety studies with genistein in rats. Food Chem Toxicol 2007, 45:1319-1332.
43. McClain R.M., Wolz E., Davidovich A., Pfannkuch F., Bausch J. Subchronic and chronic safety studies with genistein in dogs. Food Chem Toxicol 2005, 43:1461-1482.
44. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.